Innovative Models to Empower Antibody Discovery

We employ cutting-edge technology platforms to accelerate the discovery of novel therapeutics.

About Us

Clinical Pipeline

Our team has established more than 10 R & D pipelines, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.

Learn More

Antibody Discovery Services

Our state-of-the-art screening technologies capture high-quality antibody sequences on an accelerated timeline.

Learn More

RenMab™: Fully Human Antibody Mouse

Our humanized RenMab™ and RenLite™ mice are powerful platforms for generating fully human antibodies in various formats.

Visit Renmab.com

Evaluate Immunotherapies in vivo Using Humanized Immune Checkpoint Mice

Carefully designed and generated to maintain biological function for reliable drug validation.

View Our Models

Efficacy Services for Drug Development

Expert in vitro and in vivo antibody efficacy & toxicity testing to
get you from research to clinical trials faster.

View Our Services

Gene Editing Services

We offer CRISPR-Cas9-based gene editing
with superior efficiency and strict quality control.

Learn More

Quality Animal Models for Improved Clinical Translation

Custom models and humanized models you can trust to ensure
your research’s success.

View Our Animal Models
Cutting-Edge

Technologies

We are a clinical stage biopharmaceutical company that integrates proprietary gene editing technology, transgenic mouse platforms to generate fully human antibodies, comprehensive animal models and high-throughput in vivo antibody discovery. We have established fully integrated research and development capabilities ranging from early target discovery to clinical development. Our focus on research and development and technological innovation serves as the cornerstone of our continuing growth. We intend to develop and commercialize first-in-class or best-in-class drugs to contribute to the improvement of human health worldwide.

Innovative Models to Transform Antibody Discovery

Contact Us Today
Biocytogen

Global Leaders in Genetically Modified Model Generation to Empower Antibody Discovery

Founded in 2008, Biocytogen has become a global leader in gene-edited animal and cell model production. We have locations in Beijing, Jiangsu, Shanghai, and Boston, employing more than 1200 people around the world, many of whom have advanced degrees in their fields. Over the last 10 years, we have collaborated with top pharmaceutical companies and researchers to complete more than 4,500 gene editing projects. Our fast turnaround times and dedication to superior customer service have set us apart, earning us a 98 percent customer satisfaction rating. 

Whether you need custom gene editing services, fully human antibody discovery services or antibody efficacy evaluation services, we will use our cutting-edge technology platforms to provide fast and reliable solutions for your therapeutic antibody discovery projects. Contact us today to learn more about our services and discover how we could assist with your next project.

Meet the Experts
Upcoming

News & Events

Biocytogen/Eucure Biopharma’s CTLA-4 and CD40…

BOSTON and BEIJING, July 6, 2021 --Eucure Biopharma, a wholly owned subsidiary of…

Learn More
Biocytogen Completes a New Round…

BEIJING and BOSTON, June 22, 2021- Biocytogen, an international biotechnology company focused on…

Learn More
Customer Stories

Publications

Our models have been published in world’s leading journals.

View all client publications

Checkpoint inhibition through small molecule-induced…

Programmed death-ligand 1 is a glycoprotein expressed on antigen presenting cells, hepatocytes, and tumors which upon interaction with programmed death-1, results in inhibition of antigen-specific T cell responses. Here, we…

Read More

B7-H3×4-1BB bispecific antibody augments antitumor…

Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. Here, we developed a bispecific antibody (bsAb; B7-H3×4-1BB), targeting human B7-H3 (hB7-H3) and mouse or human…

Read More

Back to top